Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 186

Cited In for PubMed (Select 8257416)

2.

Comparative evaluation of the impact on endothelial cells induced by different nanoparticle structures and functionalization.

Landgraf L, Müller I, Ernst P, Schäfer M, Rosman C, Schick I, Köhler O, Oehring H, Breus VV, Basché T, Sönnichsen C, Tremel W, Hilger I.

Beilstein J Nanotechnol. 2015 Jan 27;6:300-12. doi: 10.3762/bjnano.6.28. eCollection 2015.

3.

mTOR kinase: a possible pharmacological target in the management of chronic pain.

Lisi L, Aceto P, Navarra P, Dello Russo C.

Biomed Res Int. 2015;2015:394257. doi: 10.1155/2015/394257. Epub 2015 Jan 1. Review.

4.

Hedgehog/GLI and PI3K signaling in the initiation and maintenance of chronic lymphocytic leukemia.

Kern D, Regl G, Hofbauer SW, Altenhofer P, Achatz G, Dlugosz A, Schnidar H, Greil R, Hartmann TN, Aberger F.

Oncogene. 2015 Feb 2. doi: 10.1038/onc.2014.450. [Epub ahead of print]

PMID:
25639866
5.

Involvement of Phosphatidylinositol 3-kinase in the regulation of proline catabolism in Arabidopsis thaliana.

Leprince AS, Magalhaes N, De Vos D, Bordenave M, Crilat E, Clément G, Meyer C, Munnik T, Savouré A.

Front Plant Sci. 2015 Jan 12;5:772. doi: 10.3389/fpls.2014.00772. eCollection 2014.

6.

Signaling via PI3K/FOXO1A pathway modulates formation and survival of human embryonic stem cell-derived endothelial cells.

Merkely B, Gara E, Lendvai Z, Skopál J, Leja T, Zhou W, Kosztin A, Várady G, Mioulane M, Bagyura Z, Németh T, Harding SE, Földes G.

Stem Cells Dev. 2015 Apr 1;24(7):869-78. doi: 10.1089/scd.2014.0247. Epub 2014 Dec 22.

PMID:
25387407
7.

Activation of 3-phosphoinositide-dependent kinase 1 (PDK1) and serum- and glucocorticoid-induced protein kinase 1 (SGK1) by short-chain sphingolipid C4-ceramide rescues the trafficking defect of ΔF508-cystic fibrosis transmembrane conductance regulator (ΔF508-CFTR).

Caohuy H, Yang Q, Eudy Y, Ha TA, Xu AE, Glover M, Frizzell RA, Jozwik C, Pollard HB.

J Biol Chem. 2014 Dec 26;289(52):35953-68. doi: 10.1074/jbc.M114.598649. Epub 2014 Nov 10.

PMID:
25384981
8.

Complex impacts of PI3K/AKT inhibitors to androgen receptor gene expression in prostate cancer cells.

Liu L, Dong X.

PLoS One. 2014 Oct 31;9(10):e108780. doi: 10.1371/journal.pone.0108780. eCollection 2014.

9.

TAT-protein blockade during ischemia/reperfusion reveals critical role for p85 PI3K-PTEN interaction in cardiomyocyte injury.

Zhu X, Shao ZH, Li C, Li J, Zhong Q, Learoyd J, Meliton A, Meliton L, Leff AR, Vanden Hoek TL.

PLoS One. 2014 Apr 21;9(4):e95622. doi: 10.1371/journal.pone.0095622. eCollection 2014.

10.

PI3Kγ integrates cAMP and Akt signalling of the μ-opioid receptor.

Madishetti S, Schneble N, König C, Hirsch E, Schulz S, Müller JP, Wetzker R.

Br J Pharmacol. 2014 Jul;171(13):3328-37. doi: 10.1111/bph.12698.

11.

Targeting the phosphoinositide 3-kinase pathway in hematologic malignancies.

Jabbour E, Ottmann OG, Deininger M, Hochhaus A.

Haematologica. 2014 Jan;99(1):7-18. doi: 10.3324/haematol.2013.087171. Review.

12.

PTEN/PI3K and MAPK signaling in protection and pathology following CNS injuries.

Walker CL, Liu NK, Xu XM.

Front Biol (Beijing). 2013 Aug 1;8(4). doi: 10.1007/s11515-013-1255-1.

13.

Inhibition of phosphoinositol 3 kinase contributes to nanoparticle-mediated exaggeration of endotoxin-induced leukocyte procoagulant activity.

Ilinskaya AN, Man S, Patri AK, Clogston JD, Crist RM, Cachau RE, McNeil SE, Dobrovolskaia MA.

Nanomedicine (Lond). 2014 Jul;9(9):1311-26. doi: 10.2217/nnm.13.137. Epub 2013 Nov 27.

14.

Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics.

Akinleye A, Avvaru P, Furqan M, Song Y, Liu D.

J Hematol Oncol. 2013 Nov 22;6(1):88. doi: 10.1186/1756-8722-6-88. Review.

15.

Direction pathway analysis of large-scale proteomics data reveals novel features of the insulin action pathway.

Yang P, Patrick E, Tan SX, Fazakerley DJ, Burchfield J, Gribben C, Prior MJ, James DE, Hwa Yang Y.

Bioinformatics. 2014 Mar 15;30(6):808-14. doi: 10.1093/bioinformatics/btt616. Epub 2013 Oct 27.

16.
17.

Phosphoinositides: tiny lipids with giant impact on cell regulation.

Balla T.

Physiol Rev. 2013 Jul;93(3):1019-137. doi: 10.1152/physrev.00028.2012. Review.

18.

Role of inositol phospholipid signaling in natural killer cell biology.

Gumbleton M, Kerr WG.

Front Immunol. 2013 Mar 6;4:47. doi: 10.3389/fimmu.2013.00047. eCollection 2013.

19.

Phosphoinositide-3-kinases p110α and p110β mediate S phase entry in astroglial cells in the marginal zone of rat neocortex.

Müller R, Fischer C, Wilmes T, Heimrich B, Distel V, Klugbauer N, Meyer DK.

Front Cell Neurosci. 2013 Mar 14;7:24. doi: 10.3389/fncel.2013.00024. eCollection 2013.

20.

Rapalogs and mTOR inhibitors as anti-aging therapeutics.

Lamming DW, Ye L, Sabatini DM, Baur JA.

J Clin Invest. 2013 Mar;123(3):980-9. doi: 10.1172/JCI64099. Epub 2013 Mar 1. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk